Replimune (REPL) Cash from Financing Activities (2018 - 2026)
Replimune (REPL) reported Cash from Financing Activities of $55.7 million for Q1 2026, up 42279.55% on a YoY basis from N/an in Q1 2025, and up 432.74% sequentially from $10.5 million in Q4 2025.
Replimune (REPL) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Replimune (REPL) has 9 years of Cash from Financing Activities data on file, last reported at $55.7 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 42279.55% year-over-year to $55.7 million; the trailing twelve-month figure through Mar 2026 stood at $66.3 million (down 73.73% YoY), and the FY2026 full-year result was $66.3 million, down 73.73% from the prior year.
- Cash from Financing Activities advanced to $55.7 million in Q1 2026, from $10.5 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $271.4 million in Q4 2022 to a low of -$158000.0 in Q2 2025.
- A 5-year average of $38.0 million and a median of $1.1 million in 2023 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities slumped 121.45% in 2023 and soared 42279.55% in 2026, its largest moves.
- Tracing REPL's Cash from Financing Activities over 5 years: stood at $271.4 million in 2022, then slumped by 94.52% to $14.9 million in 2023, then soared by 948.62% to $155.9 million in 2024, then plunged by 93.3% to $10.5 million in 2025, then soared by 432.74% to $55.7 million in 2026.
- Business Quant data shows REPL's Cash from Financing Activities at $55.7 million in Q1 2026, $10.5 million in Q4 2025, and $324000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | 55.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.68 Mn |
| Mar 31, 2026 | 55.68 Mn |
| Dec 31, 2025 | 10.45 Mn |
| Dec 31, 2025 | 10.45 Mn |
| Sep 30, 2025 | 324,000.00 |
| Sep 30, 2025 | 324,000.00 |
| Jun 30, 2025 | -158,000.00 |
| Jun 30, 2025 | -158,000.00 |
| Mar 31, 2025 | -132,000.00 |
| Mar 31, 2025 | -132,000.00 |
| Dec 31, 2024 | 155.93 Mn |
| Dec 31, 2024 | 155.93 Mn |
| Sep 30, 2024 | -39,000.00 |
| Sep 30, 2024 | -39,000.00 |
| Jun 30, 2024 | 96.64 Mn |
| Jun 30, 2024 | 96.64 Mn |
| Mar 31, 2024 | -130,000.00 |
| Mar 31, 2024 | -130,000.00 |
| Dec 31, 2023 | 14.87 Mn |
| Dec 31, 2023 | 14.87 Mn |